Johnson & Johnson Reports $24 Billion Q3 Sales Driven by Innovative Medicines
Written by Emily J. Thompson, Senior Investment Analyst
Source: Fool
- Sales Growth: Johnson & Johnson reported total sales of $24 billion in Q3, reflecting a 6.8% year-over-year increase, demonstrating strong performance in innovative medicines despite challenges from patent expirations.
- Innovation-Driven Growth: The company's oncology products, including Darzalex and Carvykti, are driving sales growth, with management aiming to become a global leader in oncology by 2030, further solidifying its market position.
- FDA Approvals: Johnson & Johnson's Rybrevant and Inlexzo received FDA approval in 2025, with Rybrevant projected to generate peak annual revenue of $5 billion, while Inlexzo offers a new treatment option for bladder cancer patients, changing clinical practice.
- Robust Pipeline: The company has over 20 novel therapies in development and expects to launch 50 new products by 2030, showcasing its ongoing innovation capabilities and competitive strength in the pharmaceutical industry.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JNJ is 207.26 USD with a low forecast of 176.00 USD and a high forecast of 230.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 206.910
Low
176.00
Averages
207.26
High
230.00
Current: 206.910
Low
176.00
Averages
207.26
High
230.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
